LaNova Medicines Kicks Off Phase 1 Trial for LM-299
LaNova Medicines Limited has announced the initiation of a Phase 1 clinical trial for LM-299, an advanced anti-PD-1/VEGF bispecific antibody designed for treating advanced solid tumors. The trial commenced after successful preclinical studies highlighted its effectiveness in inhibiting tumor growth while showcasing a favorable safety profile.
Breakthrough Antibody Innovations
LM-299 stands out due to its unique ability to target both PD-1 and VEGF, which can significantly enhance anti-tumor immunity combined with anti-angiogenic effects. This innovative bispecific antibody has a clever molecular design involving an anti-VEGF component linked with a C-terminal anti-PD-1 segment. Preliminary studies have validated that it effectively inhibits the PD-1 and VEGF pathways.
Future Plans for Clinical Trials
The company is also laying out plans to submit an Investigational New Drug (IND) application for LM-299 in the US, anticipated to be submitted in the latter half of the year. This strategic move is poised to broaden the reach and potential applications of the drug beyond its current focus.
Successful Series C1 Financing
In addition to launching its Phase 1 trial, LaNova has successfully completed a $42 million Series C1 financing round. This funding will accelerate the development of its clinical pipeline, particularly focusing on promising candidates like LM-299, LM-302, and LM-108. The financing was led by prominent investors including Sino Biopharmaceuticals, with both new and existing investors contributing to this significant milestone.
Clinical Developments Across Multiple Programs
LaNova is committed to advancing its leading therapeutic candidates. LM-302 is currently undergoing a Phase III clinical trial for gastric cancers, being recognized as a top contender worldwide for this indication. Simultaneously, LM-108 has progressed into Phase II trials for various solid tumors, solidifying its position as a noteworthy immunotherapeutic approach.
Commitment to Innovation and Patient Care
Dr. Crystal Qin, LaNova's founder and CEO, emphasized the company’s unwavering dedication to original innovation in cancer therapies. LaNova aims to deliver novel biologics that specifically target the tumor microenvironment. Their culture fosters collaboration and resilience in the pharmaceutical landscape and they aim to bring transformative treatment solutions to patients globally.
Understanding Its Unique Therapeutic Approach
LaNova's sophisticated R&D engine is pivotal for developing such unique treatments, leveraging three proprietary platforms that facilitate variable modality development. This allows the company to tackle challenging targets and advance multiple innovative programs, nurturing a diverse pipeline of monoclonal antibodies, ADCs, and bispecific antibodies.
Frequently Asked Questions
What is the purpose of the Phase 1 trial for LM-299?
The Phase 1 trial aims to evaluate the safety and efficacy of LM-299 in treating patients with advanced solid tumors.
Who led the recent Series C1 financing for LaNova Medicines?
The Series C1 financing was primarily led by Sino Biopharmaceuticals, attracting both new and existing investors.
How does LM-299 work?
LM-299 is designed to block both PD-1 and VEGF pathways, enhancing the body’s immune response while preventing tumor blood supply.
What are the future developments for LaNova Medicines?
LaNova plans to submit an IND for LM-299 in the US and continue advancing its pipeline including LM-302 and LM-108.
When did LaNova Medicines get founded?
LaNova Medicines was founded in September 2019 and has rapidly progressed in developing innovative therapeutic solutions.
